tirzepatide and sleepiness Eli Lilly's gained FDA approval in December 2024 for treating moderate-to-severe obstructive sleep apnea in adults with obesity, after Phase III trials showed a 20% average weight loss a roughly Does Tirzepatide Make You Tired?

Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD

Harnessing immunomodulation to combat sarcopenia: current insights and possible approaches

The therapeutic window is wide

Go over all risks with your clinician when deciding if a GLP-1 is right for you

Another potent oral PARP1/2 inhibitor, niraparib (MK4827) binds to the active site of PARP enzymes, and studies indicate that Niraparib can restore NAD + levels and improve mitochondrial function 165,166

1 In the Wegovy pill clinical trial, 6.9% of patients treated with Wegovy pill and 5.9% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions